This prospective study compared the donor experience of blood cell (BC) mobilization and leukapheresis (n ¼ 116) with that of bone marrow (BM) harvest (n ¼ 55). Internal jugular catheters were inserted electively in 89% of BC donors. Most (80%) BM donors had a harvest with general anesthesia; 20% had epidural or spinal anesthesia. Pain and fatigue were frequent with both procedures and were compared in responses to questionnaires. A total of 85% of BM donors reported moderate or severe pain compared with 68% of BC donors (P ¼ 0.02). The median duration of pain was 14 days for BM donors compared with 3 days after BC mobilization (Po0.0001). More BM donors had pain for more than 7 days (75% vs 0%, Po0.0001). Severe fatigue was experienced by more BM donors (49 vs 16%, Po0.0001). Fatigue lasted significantly longer in BM donors (median 11 vs 4 days, Po0.0001) and more BM donors were fatigued for more than 1 week (69 vs 0%, Po0.0001). A total of 11 donors had both BM and BC collection; seven preferred the latter. Simply considered with respect to pain and fatigue, BC donation appears better tolerated by donors. However, there are other sequelae of both influencing the acceptability for individual donors.
In recent years, there has been a substantial increase in the use of cytokine-mobilized blood cells (BCs) or peripheral blood stem cells (PBSC), as an alternative to bone marrow (BM) for allogeneic stem cell transplantation (SCT). Over 40% of the related donor SCTs in adults reported to the IBMTR in 1998-2000 were BC transplants (BCTs). 1 While serious complications have been reported, the experience generally appears to be safe for the donor. There is limited information regarding the subjective experience of BC donors compared with those giving BM. [35] [36] [37] [38] [39] We initiated a single center prospective study in 1993 to assess BC donor experience. In 1995, we began to compare donor experiences with the two collection procedures and to record any adverse effects in the years after BC donation.
Donors and methods
A combined total of 171 donors participated in the study. The 116 BC donors were recruited between April 1993 and November 1997. A total of 55 marrow donors were recruited from September 1995 to November 1997. No donors refused to participate in the study. Donors were from the adult outpatient service of a provincial BC and BM transplant program. The study began using only BC donors, and then expanded to compare the two donor populations. There was no randomization. In general, BM donors were giving to recipients who were unrelated or were related with chronic myelogenous leukemia (CML) or nonmalignancies. Table 1 gives some characteristics of the 116 BC donors and summarizes their mobilization and collection procedures. All donors had a full history and physical examination, blood counts, serum chemistry, and viral serology. Electrocardiogram and chest X-ray was done on donors over 40 years of age. A pregnancy test was performed on women of childbearing age.
BC donors
The past medical history of BC donors revealed thalassemia minor (2), hematochromatosis (1), cervical cancer (1), Graves' disease treated with I 131 (1), diabetes (4), and asthma (6) . Cardiovascular problems included prior myocardial infarct and angioplasty (1), arrythmias (3), hypertension (9) , and valve dysfunction (3) .
As a program standard, G-CSF was given as a multiple of 300 and 480 mg vials. In a preliminary dose-finding study, doses ranged between 5 and 16 mg/kg; a final daily dose of 7.5-10 mg/kg was selected. 4 In all, 22 donors had less than 7.5 mg/kg, 13 had more than 10 mg/kg. Blood CD34 þ cell counts were monitored daily and leukapheresis was performed on day 3 or 4, with day 0 being the day of the first injection. Early in the study, some donors had peripheral venous access, but we shortly established a routine to insert internal jugular catheters under a local anesthetic, using radiologic guidance. 41 The details of BC mobilization and collection are reported elsewhere. 4 A total of 13 BC donors had a prior or subsequent BM harvest; in nine of these, BM harvest took place before the study, the other four were included in both BC and BM donor group studies. Eleven were asked if they had a preference for one of the procedures.
BM donors
The characteristics of BM donors are shown in Table 1 . Pre-transplant screening was similar to BC donors. The medical problems included: hypertension (1), asthma (3), arrhythmia treated with digoxin (1), and sleep apnea (1) . In all, 45 donors had general anesthetic, nine had spinal anesthetic (donor request), and one donor who was 16 weeks pregnant was given an epidural anesthetic.
Marrow harvest was conducted using multiple large-bore needle punctures with no more than 10 ml aspirated from any one site. Target yields depended on the clinical circumstances, but were a minimum of 2 Â 10 8 kg recipient weight. Donors were given a prescription for acetaminophen with Codeine (or an alternative in the event of intolerance).
In all, 17 marrow donors had autologous blood stored; 16 had the units infused back following the harvest. One unrelated donor refused to have the unit reinfused.
Donors were day surgical patients and usually discharged home in the afternoon.
Data collected from donors
Donors began recording information on the first day of G-CSF injections or the marrow harvest day. A checklist required donors to evaluate the degree of pain and fatigue (scored as mild, moderate or severe) and to record the presence of other symptoms, as listed in Figure 2 and Table 2 . In addition, nursing records of the mobilization and collection were reviewed. Day 0 in this study refers to the first day of G-CSF injections in BC donors and the marrow harvest day in BM donors. On the day after the procedure, a nurse met with the donor and reviewed the data collected. Donors recorded symptoms until they were symptom free. A nurse phoned the donors weekly to ask about their well being until symptoms disappeared. BC donors were followed yearly by a letter or phone call; a blood count was requested at this time. Three nurses were responsible for data collection, data entry, and follow-up.
Informed consent
All donors and patients signed the consent forms approved by the University of Calgary Conjoint Ethics Review Board. BC donation was not an option for unrelated donors. Patients with malignant disease other than CML in chronic phase were eligible for studies of BC transplantation. One such patient had a BM transplant because of donor preference.
Statistical analysis
The proportion of BC or BM donors experiencing different intensities of pain and fatigue were compared using Fisher's exact test. The duration of pain and fatigue was evaluated using the Wilcoxon rank sum test. Analysis was performed using S-Plus 2000 software (Mathsoft Inc., Seattle, WA, USA).
Results
The frequent complications common to both procedures were bone pain and fatigue.
Pain
Bone pain in BM donors was at the site of the multiple needle aspirations, whereas that experienced after G-CSF in BC donors was widespread.
Bone pain was in the back in 68 BC donors, hips in 43, legs in 26, sternum in 19, generalized in 12, and other areas in the remainder. In all, 23 donors had pain in only one site; the remainder had pain in more than one site.
All except three BM donors had severe pain on the first post operative day. Although most donors (96% BM, 92% BC) experienced some discomfort, pain was more intense and lasted longer in BM donors. A total of 85% of BM Figure 2 ). In total, 75% of BM donors had more than 1 week of pain compared with no BC donors (Po0.0001).
Fatigue
Fatigue was commonly reported with both procedures, by 88% of BM donors and 77% of BC donors (P ¼ ns). In all, 71% of BM donors experienced moderate or severe fatigue compared with 49% of BC donors (P ¼ 0.05, Figure 1 ). The figures for severe fatigue considered separately were 49 and 16%, respectively (Po0.0001). Fatigue lasted significantly longer in BM donors, a median of 11 days (range 1-38) compared with 3 days (range 1-6) after BC donation (Po0.0001, Figure 2 ). Altogether, 69% of BM donors had fatigue for more than 1 week compared with no BC donors (Po0.0001).
Other sequelae Figure 3 illustrates the frequency of symptoms with an incidence greater than 10% in one or both groups.
Headache was mostly seen in BC donors and was less severe than bone pain. Of the 74% of BC donors with headache, 53% described it as mild, 31% moderate, and 16% severe. Headache was generalized in 33 donors, frontal in 23, and occipital in 11. Some less common sequelae are summarized in Table 2 . One BC donor was found to be pregnant following the BC collection. A pregnancy test taken 3 days before G-CSF was negative. At 5 days after the collection, a home test was positive. This test result was confirmed in the laboratory. The donor was advised that the risks of G-CSF were unknown, but she decided to have an abortion largely for financial reasons.
Blood counts
The median precollection platelet count for BC donors was 247 Â 10 9 /l (range 156-467), falling to a median of 132 Â 10 9 /l (range 30-283) the day after collection. In 14 cases (12%), platelets fell below 100 Â 10 9 /l on the day after BC collection, and three fell below 70 Â 10 9 /l to levels of 30, 56, and 68 Â 10 9 /l. In BM donors, the median presurgical hemoglobin level was 141 g/l (range 107-171) and the median the day after the harvest was 116 g/l (range 85-146). In five donors, the hemoglobin count fell below 100 g/l, the lowest being 85 g/l. Platelets were unaffected in these donors, none of whom received G-CSF.
Donors undergoing both procedures
Of 11 donors who had both BM and BC collection, seven preferred the latter. Pain, fatigue, and recovery time were given as reasons. Of the four donors preferring BM harvest, three cited the discomfort of venous access (two jugular, one femoral). The fourth felt that too much time was required for G-CSF injections.
Long-term follow-up
Two BC donors refused further participation in the study as their recipients had died, and the recall for blood counts was a painful reminder. Nine donors were lost in follow-up. The remaining 105 were followed for 1-5 years (median 2). 
Mobilized blood cells vs bone marrow harvest L Karlsson et al
Two BC donors developed cancer; one (aged 69) developed colon cancer, the second developed bladder and prostate cancer and is now deceased. A 34-year-old BC donor developed Guillain-Barre syndrome and another became hyperthyroid.
In all, 85 BC donors had 1-5 annual blood counts (median 2), with no significant changes compared with counts before donation.
Discussion
The trend toward the use of allogeneic BCT will doubtless continue in the light of recent randomized studies, some of which demonstrate a relative advantage of this source, at least in some patient subgroups. 6, [23] [24] [25] [26] 33 However, in many circumstances, BM remains an acceptable source of stem cells. The relative morbidity of BM or BCTs over the long term, particularly from chronic GVHD, has yet to be evaluated. Given the lack of demonstrable differences in the risk to donors, the issue of perceived tolerability of obtaining stem cells from BM or BC collections therefore remains important.
We found that the intensity and duration of both pain and fatigue were significantly greater in BM donors. Clearly, the nature of the pain was different for the two groups. Other effects of the procedures, either common to both or largely restricted to one or the other, were observed and are similar to other reports of BM and BC donation. We cannot evaluate the contribution of these to the tolerability of the procedures as a whole or determine their influence on the preferability of one procedure over the other.
There are some published reports available, comparing the procedures in concurrently observed groups in the context of randomized studies. Fortanier et al compared anxiety and pain in BM and BC donors. Severe pain from G-CSF, measured on a visual analogue scale, was recorded in 36% of donors compared with 20% in our study. 35 However, they did not observe a difference in pain level between BC and BM donors. The duration of pain was not recorded. A small randomized study by Heldal et al found that the total burden of complaints and analgesic usage was higher in BM donors compared with those giving BC. 36 Finally, Rowley et al reported that BC and BM donors experienced similar peak levels of pain, but that pain lasted longer in BM donors. 37 Fatigue does not appear to have been compared directly. We found that it was a frequent complaint and, in BM donors, is probably attributable in part to anemia. This institution's practice of routinely inserting an internal jugular catheter into BC donors is relatively unusual and controversial. 41 Line insertion under imaging seems to be safe; since the closure of this study, more than 200 additional donors have had these catheters inserted, with no major complications. It is noteworthy, however, that the preference for BM donation expressed by three donors was related to discomfort from line insertion. Significant distress can be alleviated in most BC donors with appropriate anesthesia, sedation, and operator technique. Jugular line access allows the vast majority of collections to be performed in a single leukapheresis, and avoids the additional distress of large vein cannulation if peripheral access fails. 4 Our study indicates that both procedures are reasonably well tolerated, with all donors recovering within a few weeks. The tolerability of stem cell collection for the donor is but one factor influencing the choice of product. If there is a demonstrable advantage to the patient for one source or the other, the procedure should be selected on this basis. In the absence of such evidence, our data suggest that, at least with respect to pain and fatigue, BC donation is easier to tolerate. No serious consequences attributable to giving G-CSF have been identified in the early years after BC donation; this is consistent with most other reports, although severe effects have been described. [30] [31] [32] Information from this study is now incorporated into our standard teaching brochure to educate future donors about the potential side effects and expected recovery time with each procedure. This includes a recommendation about the effective contraception in women of childbearing age.
